IonQ Speeds Quantum-Accelerated Drug Development Application With AstraZeneca, AWS, and NVIDIA
COLLEGE PARK, Md.--(BUSINESS WIRE)--Jun 9, 2025--
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop and demonstrate a quantum-accelerated computational chemistry workflow which has the potential to power world-changing innovation in healthcare, life sciences, chemistry, and more.
The results of the collaboration will be showcased at the ISC High Performance conference, which takes place on June 10-13, 2025, in Hamburg, Germany.
The IonQ-designed workflow provides an end-to-end example of a hybrid quantum-classical workflow that helps provide solutions to complex pharmaceutical development challenges, and has the potential to improve speed and efficiency within the drug development process. Developing new drugs can take ten or more years and cost billions of dollars, so advancements that streamline early-stage research and reduce computational bottlenecks can unlock significant strategic and commercial value.
This demonstration focused on a critical step in a Suzuki-Miyaura reaction – a class of chemical transformations used for the synthesis of small molecule drugs. By integrating IonQ's Forte quantum processing unit (QPU) with the NVIDIA CUDA-Q platform through Amazon Braket and AWS ParallelCluster services, the team achieved more than 20 times improvement in end-to-end time-to-solution compared to previous implementations. The technique maintained accuracy while reducing the overall expected runtime from months to days.
'This demonstration with AstraZeneca represents a meaningful step toward practical quantum computing applications in chemistry and materials science and showcases how IonQ's enterprise-grade quantum computers are uniquely suited to meet the challenge,' said Niccolo de Masi, CEO of IonQ. 'The ability to model catalytic reactions with speed and accuracy isn't just a scientific achievement, it's a preview of how hybrid computing with quantum acceleration will provide revolutionary capabilities to the industry.'
'This collaboration marks an important step towards accurately modeling activation barriers for catalyzed reactions relevant to route optimizing in drug development. We look forward to further advancements in the area,' said Anders Broo, Executive Director, Pharmaceutical Science, R&D, AstraZeneca.
'Future quantum computers are not going to replace traditional compute, but instead accelerate specific, computationally intensive processing steps as part of HPC processing pipelines,' said Eric Kessler, GM of Amazon Braket at AWS. 'By combining quantum computers on Amazon Braket with scalable GPU resources on AWS, we're supporting AstraZeneca to envision how future quantum computers will be used to accelerate research in computational chemistry.'
'Bringing together state-of-the-art quantum and GPU computing in hybrid workflows is the path to realizing quantum's potential,' said Tim Costa, Senior Director of Quantum and CUDA-X at NVIDIA. 'This work represents a meaningful step towards applying quantum accelerated supercomputing to important use cases.'
IonQ and its partners demonstrated a large-scale, end-to-end simulation of a Suzuki-Miyaura reaction, which is the most complex chemical simulation run on IonQ hardware to date. The hybrid quantum-classical workflow – orchestrated via CUDA-Q on Amazon Braket, accelerated with NVIDIA H200 GPUs through AWS ParallelCluster – delivered more than a 20x speedup in time-to-solution compared to prior benchmarks. This advancement highlights the scalability of IonQ's quantum systems and their practical potential in pharmaceutical R&D.
These results show how hybrid quantum computing can overcome computational limits in high-accuracy molecular modeling and enables the analysis of more complex chemical systems. It builds on recent IonQ demonstrations of practical applications where hybrid quantum-classical approaches outperformed purely classical methods.
For more information on this research, please visit the IonQ booth #A25 at the ISC High Performance conference in Hamburg, Germany on June 10-13, 2025 or read the full research paper at our technical blog post.
About IonQ
IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'accessible,' 'aimed,' 'available,' 'can,' 'cutting-edge,' 'delivering,' 'enables,' 'growth,' 'innovative,' 'impactful,' 'latest,' 'leader,' 'leading,' 'making,' 'potential,' 'provide,' 'solving,' 'toward,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, significance, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; and IonQ's ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250609358259/en/
CONTACT: IonQ Media contact:
Jane Mazur
[email protected] Investor Contact:
[email protected]
KEYWORD: GERMANY EUROPE UNITED STATES NORTH AMERICA MARYLAND
INDUSTRY KEYWORD: SOFTWARE RESEARCH NETWORKS INTERNET HARDWARE PHARMACEUTICAL DATA MANAGEMENT TECHNOLOGY SEMICONDUCTOR SCIENCE BIOTECHNOLOGY HEALTH OTHER SCIENCE
SOURCE: IonQ
Copyright Business Wire 2025.
PUB: 06/09/2025 07:05 AM/DISC: 06/09/2025 07:05 AM
http://www.businesswire.com/news/home/20250609358259/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
40 minutes ago
- TechCrunch
Suite AI: how SAP is bringing AI to the enterprise
As the adoption of AI increases, hear how SAP is expanding its AI capabilities across the business suite. By catching up with this TechCrunch Sessions: AI panel, you can see how to leverage upcoming innovations to boost efficiency, streamline processes, and drive greater engagement across your business. Plus, you'll get the opportunity to learn about SAP's AI agent Joule, embedded AI capabilities, and custom AI development. And you can check out the rest of our Sessions: AI programming right here.
Medscape
an hour ago
- Medscape
Spironolactone Offers No CV Benefit in Dialysis Patients
VIENNA — Spironolactone, a mineralocorticoid receptor antagonist (MRA), does not reduce the rates of cardiovascular (CV) death or heart failure in patients undergoing maintenance dialysis, according to ACHIEVE trial results. In addition, the relatively high rates of hyperkalemia associated with the drug — despite a run-in period — limit its use, said lead investigator Michael Walsh, MD, PhD, Renal Research Program, Population Health Research Institute, Hamilton, Ontario, Canada, who presented the results at the 62nd European Renal Association Congress on June 6. He added: 'Cardiovascular mortality remains very high' in these patients, at the 'somewhat astounding' rate of 11% per year in the current trial. The ACHIEVE Trial Previous trials have suggested that MRAs are perhaps the 'most promising therapies' in this space, Walsh noted. He and his colleagues undertook the Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE) trial to evaluate the efficacy and safety of spironolactone. The study included patients (age, ≥ 45 y or ≥ 18 y with history of diabetes) with kidney failure receiving maintenance dialysis who were at risk of CV death. All patients underwent an active run-in where they were prescribed open-label spironolactone 25 mg/day for at least 7 weeks with no dosing adjustments followed by a final eligibility assessment to ensure they were ≥ 80% adherent to the medication and that their serum potassium levels did not exceed 6.0 mmol/L. After the run-in period, 2538 of the originally selected 3565 patients were randomized to either spironolactone 25 mg/day or matching placebo. Follow-up was at 3 months, 6 months, and then every 6 months after, assessing for outcomes, safety, drug adherence, and drug resupply. Unlike the run-in period, clinicians could reduce the dose to 25 mg/three times a week if appropriate. The average age of the patients was approximately 62 years, roughly 37% were female, and the median time that the patients had been receiving dialysis was 2 years. The primary cause of kidney failure was diabetes, in just over 40% of patients, followed by hypertension/ischemia in slightly over 25%. The trial was stopped early by the external safety and event monitoring committee for futility, meaning it did not reach the target number events, even after the target had been revised downward due to better-than-expected adherence. Walsh stated that the trial did not reach its primary outcome, with no significant difference in rates of CV death or heart failure hospitalization between the spironolactone and placebo groups at a hazard ratio (HR) of 0.92 ( P = .35). There was also no significant difference between the two treatments when stratifying the patients by sex, previous heart failure, previous coronary artery disease, and the length of time they had been receiving dialysis. Further analysis indicated there was no benefit from spironolactone over placebo when looking at cardiac and vascular deaths separately and when considering first and total heart failure hospitalizations individually. However, spironolactone was associated with an increased risk of hyperkalemia, with 123 events in the spironolactone-treated group vs 80 in the placebo group (HR, 1.54; 95% CI, 1.07-2.22). Walsh noted that, despite the strengths of its large size and the high rates of adherence, the trial is limited by having a low statistical power due to being stopped early, the use of a composite primary outcome, and the challenge in defining the patients most likely to benefit from the intervention. Important Clinical Question Session co-Chair Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, told Medscape Medical News that the study addressed an 'important clinical question,' and it is 'a pity that it didn't work out.' He noted there have been numerous studies of CV disease in patients with chronic kidney disease who are not on dialysis, but 'there have been so few trials in dialysis patients,' and there consequently remains a lot to learn in this space. As to what the current findings mean for MRAs in general in preventing CV outcomes, Gansevoort said he is 'not sure, because there are drug-specific differences between the first, second, and third generation, and we cannot extrapolate the findings with the first generation to the third.' 'Whether there ever will be a trial with the third generation in dialysis patients, I doubt, because industry will not want to fund it,' he continued, and so it will 'remain an important question.' Christoph Wanner, MD, PhD, professor of medicine and head of the Division of Nephrology, University of Würzburg, Germany, noted that even if the number of patients in the trial were increased to 4000 or 5000 it would still not 'resolve the issue.' 'I think it's the end for MRAs in dialysis,' he told Medscape Medical News , and 'we have to think about what's going wrong in dialysis patients.' 'We started with statins. They didn't work. Hemodialysis/ hemodiafiltration does work, but drugs do not work. Why is this the case? What's going on? Did we design the right trials?' Wanner continued, 'I think this is still a [relevant research] question, but at the moment, with the ACHIEVE trial, the story of MRAs in dialysis is coming to an end.' 'Everyone who deals with dialysis patients realizes there is an excess of mortality, despite advancements in the technology of dialysis over the last 50 years,' noted Walsh at the start of his presentation. He continued that there have been reductions in deaths from atheromatous CV disease among patients receiving dialysis for kidney failure, but 'importantly, the other kinds of reasons, including non-atheromatous cardiovascular disease, remain extremely high,' accounting for approximately 40% of all deaths in these patients. 'Trying to understand why there is such a high risk of cardiovascular death has been challenging,' Walsh added. ACHIEVE was funded by grants from the Canadian Institutes of Health Research (Canada), the Medical Research Future Fund (Australia), the Health Research Council (New Zealand), the British Heart Foundation (United Kingdom), the Population Health Research Institute (Canada), St. Joseph's Healthcare Hamilton Division of Nephrology (Canada), Accelerating Clinical Trials (Canada), the CanSOLVE CKD Network (Canada), and the Department of Medicine, Dalhousie University (Canada). No relevant financial relationships declared.
Bloomberg
an hour ago
- Bloomberg
Bank of Spain Cuts GDP Forecast as US Tariffs Cloud Outlook
The Bank of Spain lowered its 2025 growth forecast for the country, citing a high level of economic uncertainty due to US trade policies. Gross domestic product is expected to expand by 2.4%, down from a previous prediction of 2.7% in March, the head of the central bank, Jose Luis Escriva, said on Monday.
